Sun Pharma climbs nearly 3% on USFDA nod for Doxil

Leading drug maker Sun Pharmaceutical Industries climbed on Tuesday after its subsidiary received an USFDA approval for its Abbreviated New Drug Application (ANDA) for generic version of Doxil, Doxorubicin HCl Uposome Injection USP, 2mg/ml, packaged in 20 mg/lQmL and SO mg/25tnL single-use vials.

Doxorubicin HCl liposome injection is used to treat patients with ovarian cancer that has progressed or recurred after platinum-based chemotherapy. Shares ofthe companyare trading at Rs 738.50, up Rs 20.35, or 2.83% at the Bombay Stock Exchange (BSE) on Tuesday at 10:13 a.m.The scrip has touched an intra-day high of Rs 752.10 and low of Rs 727.60. The total volume of shares traded at the BSE is 69,319.In the earlier session, the shares declined 0.23%, or Rs 1.65, at Rs 718.15. Currently, the stock is trading down 4.82% from its 52-week high of Rs 775.90 and above 38.79% over the 52-week low of Rs 532.10.

Share Price Movement Period Pricein Rs Gain/(Loss) in Rs in % 1 Week 711.70 6.45 0.91 1 Month 734.75 (16.60) (2.26) 3 Months 701.45 16.70 2.38 6 Months 676.95 41.20 6.09 1 Year 546.30 171.85 31.46 Note: Based on previous day closing price.